Biofarm (LTS:0HTH) Marketable Securities: lei25.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HTH Biofarm SA LTS:0HTH
69 GF Score
Price lei0.24
GF Value lei0.15
! 5 Warning Signs
View Full Analysis

What is Biofarm Marketable Securities?

Biofarm LTS:0HTH 69 Marketable Securities is lei25.0 Mil as of Mar. 2026. GuruFocus rates LTS:0HTH with a GF Score™ of 69/100 and a GF Value™ of lei0.15. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Biofarm's Marketable Securities for the quarter that ended in Mar. 2026 was lei25.0 Mil.

Biofarm's annual Marketable Securities declined from Dec. 2023 (lei91.0 Mil) to Dec. 2024 (lei62.0 Mil) and declined from Dec. 2024 (lei62.0 Mil) to Dec. 2025 (lei55.0 Mil).

Biofarm  (LTS:0HTH) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Biofarm Marketable Securities Related Terms

Biofarm Marketable Securities Historical Data

* Premium members only.

The historical data trend for Biofarm's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Marketable Securities Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 91.00 62.00 55.00

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 30.00 55.00 25.00
LTS:0HTH
69GF Score
Biofarm SA LTS:0HTH
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of lei25.0 Mil mean?
Biofarm (LTS:0HTH) has a Marketable Securities of lei25.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Biofarm and its competitors.
Is Biofarm's Marketable Securities too high?
Biofarm's current Marketable Securities is lei25.0 Mil. Overall, Biofarm has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Marketable Securities compare to ZTS and UTHR?
Biofarm's Marketable Securities of lei25.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Biofarm and its competitors. Biofarm's current Marketable Securities is lei25.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current Marketable Securities of lei25.0 Mil. The stock's GF Value™ is lei0.15, compared to a current price of lei0.24 — trading 58% above its estimated fair value. The current Marketable Securities is lei25.0 Mil. Biofarm's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current Marketable Securities is lei25.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (LTS:0HTH) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei0.24 is trading 58% above its estimated GF Value™ of lei0.15.

Key valuation signals for LTS:0HTH:

  • Marketable Securities: lei25.0 Mil
  • GF Value™: lei0.15 vs. price of lei0.24 (58% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Other Exchanges BIO:Romania
Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for LTS:0HTH

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.24
Price
lei0.15
GF Value